Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

130.50
Delayed Data
As of 4:00pm ET
 -9.81 / -6.99%
Today’s Change
95.08
Today|||52-Week Range
149.31
+28.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.0B

Company Description

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Contact Information

Ligand Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard
San Diego California 92121
P:(858) 550-7500
Investor Relations:

Employees

Shareholders

Mutual fund holders63.44%
Other institutional56.42%
Individual stakeholders19.34%

Top Executives

John L. HigginsChief Executive Officer & Director
Matthew W. FoehrPresident & Chief Operating Officer
Matthew E. KorenbergCFO, Principal Accounting Officer & VP-Finance
Vincent AntleVP-Technical Operations & Quality Assurance
Charles S. BerkmanSecretary, Vice President & General Counsel